<DOC>
	<DOC>NCT02026921</DOC>
	<brief_summary>A phase II single arm study of carboplatin and docetaxel in treatment of first sensitive relapse of epithelial ovarian, peritoneal or tubal cancer. Hypothesis: Treatment with this combination in second line is safe and with a low frequency of neurologic side effect.</brief_summary>
	<brief_title>A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer</brief_title>
	<detailed_description>Evaluation of toxicity and response of treatment with carboplatin and docetaxel to patients with epithelial cancer of ovary, fallopian tube or peritoneum with their first relapse occurring at least 6 months after end of first line treatment- Evaluation of toxicity according to Clinical Toxicity Criteria version 2.</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Epithelial carcinoma of ovarian, peritoneal or fallopian tube origin. Female age above 18 years WHO performance status 02 Life expectancy &gt; 3 months Previous treatment with one platinum and taxane containing regimen. Platinum and taxane sensitive relapse At least one evaluable/measurable lesion. Adequate hematologic, renal and liver function Consent form signed and dated before inclusion Prior treatment with more than one line of chemotherapy Concurrent severe and/or uncontrolled comorbid medical condition. History of previous or concurrent malignancy within the previous 5 years • History of prior serious allergic reactions such as anaphylactic shock Pregnant or lactating women (or potentially fertile women not using adequate contraception) Peripheral neuropathy &gt; Grade 2 History of allergy to drugs containing the excipient TWEEN 80®. Concomitant administration of any other experimental drug under investigation or concurrent treatment with any other anticancer therapy Clinical evidence of brain metastases</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Phase II study,</keyword>
	<keyword>Recurrent platinum-sensitive ovarian cancer</keyword>
	<keyword>docetaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Toxicity</keyword>
</DOC>